About B-lymphocyte antigen CD20
B-lymphocyte antigen CD20 (MS4A1) is a protein
from Homo sapiens identified by UniProt accession
P11836, 297 residues long.
MolForge cross-references it against 0 known binders and
362 disease associations.
Target properties
| Protein name | B-lymphocyte antigen CD20 |
|---|
| UniProt accession | P11836 |
|---|
| Gene | MS4A1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 297 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (10)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (362)
Diseases linked to this target (Open Targets).
- chronic lymphocytic leukemia · score 0.61
- common variable immunodeficiency · score 0.61
- diffuse large B-cell lymphoma · score 0.60
- multiple sclerosis · score 0.60
- rheumatoid arthritis · score 0.60
- non-Hodgkins lymphoma · score 0.59
- follicular lymphoma · score 0.59
- relapsing-remitting multiple sclerosis · score 0.58
- autoimmune thrombocytopenic purpura · score 0.56
- Granulomatosis with Polyangiitis · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P11836-F1 | alphafold | PREDICTED | 70.52 | — |
Amino-acid sequence (297 residues)
MTTPRNSVNG TFPAEPMKGP IAMQSGPKPL FRRMSSLVGP TQSFFMRESK TLGAVQIMNG LFHIALGGLL MIPAGIYAPI CVTVWYPLWG GIMYIISGSL LAATEKNSRK CLVKGKMIMN SLSLFAAISG MILSIMDILN IKISHFLKME SLNFIRAHTP YINIYNCEPA NPSEKNSPST QYCYSIQSLF LGILSVMLIF AFFQELVIAG IVENEWKRTC SRPKSNIVLL SAEEKKEQTI EIKEEVVGLT ETSSQPKNEE DIEIIPIQEE EEEETETNFP EPPQDQESSP IENDSSP
Explore B-lymphocyte antigen CD20 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets